Bill No. 2801 amends Section 204 of the Oklahoma Health Care Authority's vendor drug program to include new provisions regarding the approval of atypical antipsychotic medications. The bill mandates that the Authority must approve prior authorization requests for any FDA-approved atypical antipsychotic not listed on the preferred drug list, specifically for the treatment and prevention of mood disorders with psychotic symptoms, such as bipolar disorder and schizophrenia. The approval process will consider the patient's claims history or healthcare provider attestation, requiring either a trial and failure of a preferred atypical antipsychotic within the past year or confirmation that the patient is stable on a non-preferred atypical antipsychotic.

Additionally, the bill ensures that medications approved under this new provision will be available at parity with other branded medications in the same class. The act is set to take effect on November 1, 2025.